Valuation: PREDILIFE

Market Cap 20.52L 22.5L 18.97L 17.12L 32.25L 21Cr 33.52L 2.29Cr 90.58L 11Cr 84.41L 82.64L 36Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 68.3L 74.89L 63.15L 56.99L 1.07Cr 70Cr 1.12Cr 7.63Cr 3.01Cr 38Cr 2.81Cr 2.75Cr 119.27Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day+0.38%
1 week-30.40%
Current month-38.59%
1 month-38.59%
3 months-53.81%
6 months-81.22%
Current year-82.66%
1 week 0.52
Extreme 0.52
0.65
1 month 0.52
Extreme 0.52
1.01
Current year 0.52
Extreme 0.52
4
1 year 0.52
Extreme 0.52
4
3 years 0.52
Extreme 0.52
24
5 years 0.52
Extreme 0.52
24
10 years 0.52
Extreme 0.52
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
27/07/23 Buy

Chief Executive Officer

1,200 0.0328%
23/03/22 Sell

Chief Executive Officer

3,000 0.0820%
09/03/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-30.40%-83.16%-91.44% 22.5L
+0.19%-2.90%+56.40%+69.15% 6.55TCr
-0.51%-3.47%+7.32%+89.88% 5.89TCr
+0.47%+0.54%+26.44%+87.46% 5.52TCr
-0.22%-2.58%+14.54%+115.68% 4.61TCr
-0.16%-4.90%+18.55%+25.59% 4.25TCr
+3.61%+3.86%+22.82%+46.39% 3.56TCr
+2.35%-5.84%+135.42%+664.13% 3.46TCr
+0.14%+0.48%+79.23%+59.77% 3.25TCr
+14.74%+22.81%-28.77%+488.95% 2.63TCr
Average +2.15%-5.14%+24.88%+155.56% 4TCr
Weighted average by Cap. +1.53%-2.69%+36.14%+152.29%

Financials

2024 2025
Net sales 5L 5L 5L 4L 8L 5.05Cr 8L 55.07L 21.77L 2.73Cr 20.29L 19.86L 8.61Cr 8L 9L 8L 7L 13.13L 8.56Cr 13.65L 93.33L 36.89L 4.62Cr 34.38L 33.66L 15Cr
Net income -42.65L -46.76L -39.43L -35.59L -67.02L -44Cr -69.66L -4.76Cr -1.88Cr -24Cr -1.75Cr -1.72Cr -74Cr -39.34L -43.14L -36.38L -32.83L -61.83L -40Cr -64.27L -4.39Cr -1.74Cr -22Cr -1.62Cr -1.58Cr -69Cr
Net Debt 35.38L 38.8L 32.72L 29.52L 55.61L 36Cr 57.8L 3.95Cr 1.56Cr 20Cr 1.46Cr 1.43Cr 62Cr 47.78L 52.39L 44.17L 39.87L 75.08L 49Cr 78.04L 5.34Cr 2.11Cr 26Cr 1.97Cr 1.92Cr 83Cr
Projected Income Statement - Annual - PREDILIFE
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
19/26/19 €0.5220 +0.38% 36
18/26/18 €0.5200 -10.65% 544
17/26/17 €0.5820 +0.34% 549
16/26/16 €0.5800 -7.94% 1,727
13/26/13 €0.6300 -16.00% 610

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - PREDILIFE
  1. Stock Market
  2. Stocks
  3. ALPRE Stock